Literature DB >> 25322915

Meta-analysis of lobectomy, segmentectomy, and wedge resection for stage I non-small cell lung cancer.

Yang Zhang1, Yihua Sun, Rui Wang, Ting Ye, Yiliang Zhang, Haiquan Chen.   

Abstract

BACKGROUND: Survival difference following lobectomy, segmentectomy, and wedge resection in stage I non-small cell lung cancer (NSCLC) and its subgroups remains undetermined.
METHODS: We systemically searched published articles comparing recurrence-free survival (RFS), overall survival (OS), or cancer-specific survival (CSS) between lobectomy and limited resection or between segmentectomy and wedge resection.
RESULTS: A total of 42 studies published from 1980 to 2014 enrolling 21,926 patients were included in this meta-analysis. Survival results favored lobectomy in stage IA NSCLC ≤2 cm (combined HR: 1.530, 95% CI: 1.402-1.671, P < 0.001) or patient's ≥65 years old (combined HR: 1.227, 95% CI: 1.003-1.502, P = 0.047). Survival outcome of video-assisted thoracoscopic (VATS) sublobectomy was comparable to that of VATS lobectomy (pooled HR: 0.808, 95% CI: 0.556-1.174, P = 0.263). The combined HR of segmentectomy versus lobectomy was 1.231 (95% CI: 1.070-1.417, P = 0.004), while the pooled HR of wedge resection versus segmentectomy was 1.542 (95% CI: 0.856-2.780, P = 0.149).
CONCLUSIONS: This study suggested that tumor size or age alone should not be the criteria to encourage sublobar resection. For stage I NSCLC, survival following segmentectomy was inferior to lobectomy. Patients undergoing intentional sublobectomy achieved comparable survival as those who received lobectomy.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  carcinoma; lobectomy; meta-analysis; non-small-cell lung; segmentectomy; stage I; wedge resection

Mesh:

Year:  2014        PMID: 25322915     DOI: 10.1002/jso.23800

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  39 in total

1.  A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032).

Authors:  Michael S Kent; Sumithra J Mandrekar; Rodney Landreneau; Francis Nichols; Nathan R Foster; Thomas A DiPetrillo; Bryan Meyers; Dwight E Heron; David R Jones; Angelina D Tan; Sandra Starnes; Joe B Putnam; Hiran C Fernando
Journal:  Ann Thorac Surg       Date:  2016-04-19       Impact factor: 4.330

2.  How to decrease technical obstacles to difficult video-assisted thoracoscopic surgery segmentectomy?

Authors:  Wolfram Karenovics; Michel Gonzalez
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

3.  Tiny lung adenocarcinomas: better prognosis with a word of caution.

Authors:  Ramón Rami-Porta
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

4.  The fundamental problem of confounding by medical operability in retrospective comparisons of surgery versus stereotactic body radiation therapy for early-stage lung cancer.

Authors:  Vivek Verma; Chad G Rusthoven
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

5.  Lobar or sublobar resection for stage I lung cancer: that is (still) the question!

Authors:  Alfonso Fiorelli; Domenico Loizzi; Mario Santini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

6.  Virtual navigation to guide personalized treatment of small-size lung cancer using minimally invasive techniques.

Authors:  Giulia Veronesi; Pierluigi Novellis; Marco Alloisio
Journal:  J Vis Surg       Date:  2016-03-30

Review 7.  Selective lymph node dissection in early-stage non-small cell lung cancer.

Authors:  Han Han; Haiquan Chen
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

8.  Spread through air spaces-positive T1 lung adenocarcinoma: is lobectomy associated with better outcomes than sublobar resection?

Authors:  Kathleen Weiss; Matthew M Rochefort
Journal:  Ann Transl Med       Date:  2019-07

9.  Intraoperative frozen sections of the regional lymph nodes contribute to surgical decision-making in non-small cell lung cancer patients.

Authors:  Wei Li; Xue-Ning Yang; Ri-Qiang Liao; Qiang Nie; Song Dong; Hao-Ran Zhai; Yi-Long Wu; Wen-Zhao Zhong
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

Review 10.  Lung cancer screening in patients with chronic obstructive pulmonary disease.

Authors:  Jessica Gonzalez; Marta Marín; Pablo Sánchez-Salcedo; Javier J Zulueta
Journal:  Ann Transl Med       Date:  2016-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.